Vir Biotechnology, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Vir Biotechnology, Inc. (VIR) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 127.74 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-05-06
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 127.74M shares, a 17.86% increase year-over-year.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 127.36M shares, a 37.60% increase year-over-year.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 125.81M shares, a 1098.10% increase year-over-year.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 114.98M shares, a 1132.69% increase year-over-year.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 119.16M shares, a 292.62% increase from fiscal 2019.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 30.35M shares, a 295.88% increase from fiscal 2018.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 7.67M shares, a 256.20% increase from fiscal 2017.
- Vir Biotechnology, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 2.15M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-03-31 | 127.74M shares 10-Q · filed 2021-05-06 | 127.55M shares derived: average of 2 quarters · filed 2021-05-06 | 126.97M shares derived: average of 3 quarters · filed 2021-05-06 | 123.97M shares derived: average of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 127.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 126.58M shares derived: average of 2 quarters · filed 2021-02-25 | 122.72M shares derived: average of 3 quarters · filed 2021-02-25 | 119.16M shares 10-K · filed 2021-02-25 |
| 2020-09-30 | 125.81M shares 10-Q · filed 2020-11-10 | 120.40M shares derived: average of 2 quarters · filed 2020-11-10 | 116.43M shares 10-Q · filed 2020-11-10 | 110.43M shares derived: average of 4 quarters · filed 2021-05-06 |
| 2020-06-30 | 114.98M shares 10-Q · filed 2020-08-11 | 111.68M shares 10-Q · filed 2020-08-11 | 105.31M shares derived: average of 3 quarters · filed 2021-05-06 | 81.61M shares derived: average of 4 quarters · filed 2021-05-06 |
| 2020-03-31 | 108.39M shares 10-Q · filed 2021-05-06 | 100.47M shares derived: average of 2 quarters · filed 2021-05-06 | 70.48M shares derived: average of 3 quarters · filed 2021-05-06 | 55.19M shares derived: average of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | 92.55M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 51.53M shares derived: average of 2 quarters · filed 2021-02-25 | 37.46M shares derived: average of 3 quarters · filed 2021-02-25 | 30.35M shares 10-K · filed 2021-02-25 |
| 2019-09-30 | 10.50M shares 10-Q · filed 2020-11-10 | 9.91M shares derived: average of 2 quarters · filed 2020-11-10 | 9.62M shares 10-Q · filed 2020-11-10 | 9.37M shares derived: average of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | 9.33M shares 10-Q · filed 2020-08-11 | 9.17M shares 10-Q · filed 2020-08-11 | 9.00M shares derived: average of 3 quarters · filed 2021-02-25 | 8.76M shares derived: average of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | 9.00M shares 10-Q · filed 2020-05-12 | 8.83M shares derived: average of 2 quarters · filed 2021-02-25 | 8.57M shares derived: average of 3 quarters · filed 2021-02-25 | |
| 2018-12-31 | 8.66M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 8.35M shares derived: average of 2 quarters · filed 2021-02-25 | 7.67M shares 10-K · filed 2021-02-25 | |
| 2018-09-30 | 8.04M shares 10-Q · filed 2019-11-19 | 7.33M shares 10-Q · filed 2019-11-19 | ||
| 2017-12-31 | 2.15M shares 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |